Mizuho analyst Anthony Petrone lowered the firm’s price target on Teleflex (TFX) to $155 from $175 and keeps a Neutral rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex price target lowered to $150 from $155 at RBC Capital
- Teleflex price target lowered to $140 from $149 at Truist
- Teleflex’s Strategic Uncertainty and Growth Challenges Justify Hold Rating
- Teleflex receives FDA 510(k) clearance of AC3 Range IABP
- Teleflex reports efficacy of Ringer PBC in coronary procedures